Clinical Trial Update: CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food Interaction [Phase 1]

View source ↗

Summary

Connecta Therapeutics reports the completion of its first-in-human Phase 1 study of CTH120 in Fragile X Syndrome, evaluating single and multiple ascending doses…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• CTH120

Snippet

Sponsor: Connecta Therapeutics, S.L. | Conditions: Fragile X Syndrome | Phase 1 | Status: COMPLETED